Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$14.63 USD
+0.38 (2.67%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $14.64 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Stoke Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -104.70 | -101.07 | -85.81 | -52.24 | -32.33 |
Depreciation/Amortization & Depletion | 2.14 | 1.34 | 1.12 | 0.89 | 0.45 |
Net Change from Assets/Liabilities | -6.03 | 43.02 | 0.05 | 2.33 | -1.11 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 27.52 | 24.84 | 17.74 | 6.81 | 1.93 |
Net Cash From Operating Activities | -81.07 | -31.87 | -66.91 | -42.22 | -31.06 |
Property & Equipment | -1.62 | -3.96 | -1.20 | -1.05 | -1.63 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 107.56 | -41.92 | -75.23 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 105.95 | -45.88 | -76.43 | -1.05 | -1.63 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 52.45 | 45.84 | 0.78 | 108.24 | 152.23 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.56 | 0.57 | 0.51 | -0.13 | -2.47 |
Net Cash from Financing Activities | 53.01 | 46.41 | 1.28 | 108.11 | 149.76 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 77.89 | -31.34 | -142.05 | 64.84 | 117.07 |
Cash at Beginning of Period | 114.13 | 145.46 | 287.51 | 222.68 | 105.60 |
Cash at End of Period | 192.01 | 114.13 | 145.46 | 287.51 | 222.68 |
Diluted Net EPS | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 |
Fiscal Year End for Stoke Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -52.07 | -26.37 | -104.70 | -77.74 | -53.20 |
Depreciation/Amortization & Depletion | 0.80 | 0.54 | 2.14 | 1.61 | 1.09 |
Net Change from Assets/Liabilities | -4.72 | -4.69 | -6.03 | -5.16 | -4.80 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.95 | 5.96 | 27.52 | 20.87 | 13.75 |
Net Cash From Operating Activities | -42.04 | -24.57 | -81.07 | -60.42 | -43.16 |
Property & Equipment | -0.06 | -0.01 | -1.62 | -1.39 | -1.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -78.23 | 10.00 | 107.56 | 92.56 | 77.56 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -78.29 | 9.99 | 105.95 | 91.18 | 76.56 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 122.20 | 1.55 | 52.45 | 45.66 | 45.10 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.17 | 0.17 | 0.56 | 0.00 | 0.00 |
Net Cash from Financing Activities | 122.37 | 1.72 | 53.01 | 45.66 | 45.10 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 2.03 | -12.86 | 77.89 | 76.42 | 78.50 |
Cash at Beginning of Period | 192.01 | 192.01 | 114.13 | 114.13 | 114.13 |
Cash at End of Period | 194.05 | 179.15 | 192.01 | 190.55 | 192.63 |
Diluted Net EPS | -0.46 | -0.57 | -0.61 | -0.55 | -0.69 |